#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thymic carcinoma Osteosarcoma Henoch-Schonlein purpura Follicular lymphoma Extra-osseous Ewing's sarcoma recurrent Congenital growth hormone deficiency Oesophageal adenocarcinoma stage III Epileptic encephalopathy Lymphatic malformation Mantle cell lymphoma recurrent Lymphoma Pemphigus Chondrosarcoma Hereditary spastic paraplegia Mucopolysaccharidosis II More trials…

    Learn about Rare Diseases

    Carcinoid syndrome – Basic Information Mitochondrial myopathy Hereditary ataxia – Life with Disease Piriformis syndrome – Life with Disease Mucopolysaccharidosis II – Diagnostics IgA nephropathy – Diagnostics Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Treatment Congenital hypotransferrinaemia – Basic Information Leukoencephalopathy – Basic Information Alexander disease – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Antiemetics And Antinauseants Levomethadone Hydrochloride SUMATRIPTAN Vosilasarm Sulfamethizole Rebisufligene Etisparvovec Linsitinib Infliximab ALN-961583 Amb-05X Alkaline Phosphatase, Bovine Zanidatamab Human Immunoglobulin G Rusfertide Befiradol (18F) Dextran 70 Vibostolimab 11902A Gadoxetic Acid, Disodium IHMA-2121771-2 More therapies…

    Learn about Your Condition

    Upper limb fracture Vulval cancer recurrent Pyoderma gangrenosum Lung adenocarcinoma Pulmonary venous thrombosis Psychological trauma Hepatic cancer Hyponatraemia Endometrial cancer stage IV Tooth loss Adenovirus infection Radicular pain Neonatal hyperglycaemia Urethral valves Mantle cell lymphoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Landeskrankenanstalten-Betriebsgesellschaft Kabeg

Landeskrankenanstalten-Betriebsgesellschaft Kabeg

Feschnigstrasse 11, Klagenfurt,09.Bez.:Annabichl, Klagenfurt am Wörthersee, 9020, Austria

Want to learn more about this study or check if you can participate? Contact us.

  • Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Austria Belgium Bulgaria France Germany Greece +4

  • VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    • VMX-C001
    Austria Belgium Bulgaria Czechia Estonia France +9

  • Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks

    Recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
    Austria Czechia Denmark France Germany Italy +3

  • Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

    Recruiting

    3 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Selatogrel
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • ORG-129
    Austria Belgium Czechia Denmark France Germany +4

  • A Phase 2b/3 Randomized Double‑Blind Study of Ataciguat to Slow Disease Progression in Adults with Moderate Calcific Aortic Valve Stenosis

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Aortic valve stenosis
    Austria Czechia France Norway Poland Portugal +1

  • Comparison of dupilumab and tezepelumab for the treatment of chronic rhinosinusitis with nasal polyps.

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Tezepelumab
    • Dupilumab
    Austria

  • Study on Mavacamten for Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Hypertrophic cardiomyopathy
    Investigated Drugs:
    • Mavacamten
    Austria Belgium Czechia Finland France Germany +5

  • A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

    Not recruiting

    3 1
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

  • A study testing trimodulin in hospitalized adult patients with community-acquired pneumonia including COVID-19 pneumonia

    Not recruiting

    3 1
    Investigated Diseases:
    • Pneumonia
    • COVID-19
    Investigated Drugs:
    • Trimodulin (Human Igm, Iga, Igg Solution)
    Austria Belgium France Germany Hungary Latvia +3
Previous Page
1 2 3 4 5 6
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!